The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Reports emerged on August 3 regarding a potential $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb. The potential deal faced skepticism from analysts due to significant regulatory hurdles in the oncology sector and concerns over the strategic rationale. However, by August 5, a senior source informed Reuters that there are no ongoing discussions between the two pharmaceutical giants regarding a potential deal.